資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34502
|
| 標題: | Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients |
| 作者: | Liu, Wen-Shan
Tsai, Kuo-Wang
Kang, Bor-Hwang
Yang, Ching-Chieh
Huang, Wei-Lun
Lee, Ching-Chih
Hu, Yu-Chang
Chang, Kuo-Ping
Chen, Hsiu-Min
Lin, Yaoh-Shiang |
| 貢獻者: | Kaohsiung Vet Gen Hosp, Dept Radiat Oncol
Meiho Univ, Dept Nursing
Natl Def Med Ctr, Sch Med
Kaohsiung Vet Gen Hosp, Dept Med Educ & Res
Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Res
Kaohsiung Vet Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg
Chi Mei Med Ctr, Dept Radiat Oncol
Chia Nan Univ Pharm & Sci, Dept Pharm
Kaohsiung Vet Gen Hosp, Ctr Med Informat, Dept Res |
| 關鍵字: | INTENSITY-MODULATED RADIOTHERAPY
QUALITY-OF-LIFE
CARCINOMA PATIENTS
RADIATION-THERAPY
LATE TOXICITY
COMORBIDITY
IMPACT
SURVIVAL
OUTCOMES
HEAD |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:59:31 (UTC+8) |
| 出版者: | ELSEVIER SCIENCE INC |
| 摘要: | Purpose: To compare the treatment outcome and severe late adverse effects (AEs) between conventional volume and dose (CVD) and simultaneously reduced volume and dose (SRVD) of clinical target volume treatments in patients with nasopharyngeal carcinoma. Methods and Materials: This retrospective cohort study enrolled patients with nonmetastatic stage II to IV nasopharyngeal cancer from a single institute. Survival endpoints and severe (>= grade 3) late AEs and comorbidity were compared between groups. The correlation of severe late AEs, comorbidity, and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression methods. Results: From January 2012 to June 2017, this study enrolled 178 patients, 64 in the CVD group and 114 in the SRVD group. The 2 groups did not differ significantly in patient characteristics except for mean follow-up time (37.6 vs 48.8 months; P = .01). The SRVD group did not significantly differ from the CVD group in local control survival (82.0% vs 78.4%; P = .85), regional control survival (89.9% vs 86.0%; P = .62), or disease-free survival (76.4% vs 66.9%; P = .67). The SRVD group had significantly better OS (93.9% vs 67.0%; P < .001) and salvage survival (79.3% vs 20.7%; P < .01) and a significantly lower ratio of severe lung infection (1 of 113 vs 5 of 59; P = .02). The SRVD group had a significantly lower risk of mortality (hazard ratio [HR], 0.3; P = .03). The factors associated with a significantly higher risk of mortality were N3 (regional lymph node stage status of N3) (HR, 3.0; P = .02); comorbidities of diabetes, coronary artery disease, or chronic kidney disease (grades 2-3) (HR, 3.8; P = .009), and severe lung infection (HR, 6.3; P = .007). Conclusions: Simultaneously reduced volume and dose of clinical target volumes did not impair locoregional control or disease-free survival. The benefits of SRVD treatment may include significant reduction in severe late AEs, particularly lung infection, dysphagia, and xerostomia. However, additional studies with longer patient follow-up are required to confirm these benefits. (C) 2020 Elsevier Inc. All rights reserved. |
| 關聯: | INT J RADIAT ONCOL, v.109, n.2, pp.495-504 |
| 顯示於類別: | [生物科技系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 196 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
